PHAGOBURN

Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa burn wound infections (Phase I-II clinical trial)

 Coordinatore MINISTERE DE LA DEFENSE 

 Organization address address: "Rue Saint Dominique, 14"
city: PARIS
postcode: 75007

contact info
Titolo: Mr.
Nome: Christophe
Cognome: Payen
Email: send email
Telefono: +33 141932684

 Nazionalità Coordinatore France [FR]
 Totale costo 4˙968˙195 €
 EC contributo 3˙838˙422 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-2
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-06-01   -   2016-05-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    MINISTERE DE LA DEFENSE

 Organization address address: "Rue Saint Dominique, 14"
city: PARIS
postcode: 75007

contact info
Titolo: Mr.
Nome: Christophe
Cognome: Payen
Email: send email
Telefono: +33 141932684

FR (PARIS) coordinator 560˙876.00
2    PHERECYDES PHARMA SA

 Organization address address: AVENUE GASTON ROUSSEL PARC BIOCITECH 102
city: ROMAINVILLE
postcode: 93230

contact info
Titolo: Dr.
Nome: Jérôme
Cognome: Gabard
Email: send email
Telefono: +33 148406535
Fax: +33 148405532

FR (ROMAINVILLE) participant 1˙565˙895.31
3 CLEAN CELLS SAS FR participant 1˙061˙710.77
4    ECOLE ROYALE MILITAIRE - KONINKLIJKE MILITAIRE SCHOOL

 Organization address address: Avenue de la Renaissance 30
city: BRUXELLES
postcode: 1000

contact info
Titolo: Ms.
Nome: Nathalie
Cognome: Pattyn
Email: send email
Telefono: +32 476661203

BE (BRUXELLES) participant 397˙259.92
5    HOSPICES CANTONAUX CHUV

 Organization address address: Rue du Bugnon 21
city: LAUSANNE
postcode: 1005

contact info
Titolo: Dr.
Nome: Yok Ai
Cognome: Que
Email: send email
Telefono: +41 21 3142905

CH (LAUSANNE) participant 252˙680.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

gmp    phage    gram    coli    burn    infections    patients    belgium    french    trial    aeruginosa    phagoburn    bacteria    resistant    wound    drug    bioproduction    becoming    mdr    combined    atb    sme   

 Obiettivo del progetto (Objective)

'Sepsis is the major problem of large burn patients and a predominant cause of death. The burn wound pathology, combined to a global intensive use of antibiotics (ATB), put patients at high risk of suffering from multidrug resistant (MDR) infections, notably carried out by the Gram-negative bacteria species: Pseudomonas aeruginosa or Escherichia coli. But the last Gram- ATB is more than 20 years old and impeded by spread out exponential resistance. New ATB with genuine mode of action to target current resistant types are out of scope. In this context, MDR Gram- infections are becoming orphan pathologies without treatment. Fighting MDR in burn trauma is becoming an urgent medical need through innovation.

PHAGOBURN is focused on a highly promising alternative to ATB: phage therapy. Bacteriophages are viruses that specifically infect and kill bacteria during their replicative cycle. The main objective of the project is to assess the safety, effectiveness and pharmacodynamics of two therapeutic phage cocktails to treat either E. coli or P. aeruginosa burn wound infections. To reach that goal, a combined Phase I/II multicentric clinical trial will be carried out in 3 EU countries (France, Belgium, Switzerland), by different hospital burn units. Prior to that, a GMP bioproduction process will be implemented to produce both drug products according to current EMA standards. Meanwhile, the production process and the trial results will provide basis for an optimization of current regulatory guidelines.

PHAGOBURN is coordinated by the French Ministry of Defence. The Consortium also includes the following partners: Pherecydes (French SME) and Clean Cells (French SME) for the GMP bioproduction of drug products, CHU Vaudois (CH) burn wards, as well as the Royal Military Academy of Belgium (Queen Astrid).'

Altri progetti dello stesso programma (FP7-HEALTH)

EURO-PADNET (2008)

The Pathophysiology and Natural Course of Patients with Primary Antibody Deficiencies (PAD)

Read More  

GIPIO (2008)

Gastro-intestinal Peptides in Obesity

Read More  

PHENOSCALE (2009)

"Large-scale, high-throughput automated systems for phenotyping mouse models of human disease"

Read More